Anna Gloyn wins 2026 Transatlantic Alliance Award in Endocrinology

The European Society of Endocrinology (ESE) and the Endocrine Society are delighted to announce Dr Anna Gloyn DPhil FMedSci, as the winner of the fifth Transatlantic Alliance Award 2026. The Transatlantic Alliance Award, launched in 2022, recognises an international leader who has made significant advancements in endocrine research on both sides of the Atlantic - in Europe and the United States. Dr Anna Gloyn has been honoured with this prestigious award for her exceptional work bridging the two continents. A globally recognised geneticist and endocrinologist, she is renowned for pioneering research that uncovers the genetic mechanisms underlying diabetes and advances precision medicine in diabetes care.

A new proof-of-concept study from researchers at Bar-Ilan University reveals a surprising finding: incorporating more walking into public transportation commutes can improve health—without adding extra travel time.

The study, part of Prof. Jonathan Rabinowitz’s More Walking Project and conducted in collaboration with the Israeli Smart Transportation Research Center (ISTRC), analyzed potential commuting routes for over 2,100 employees traveling to Bar-Ilan University. By increasing the walking distance thresholds in trip planning, researchers found that most commuters could benefit from an average of nine minutes of walking—without lengthening their total travel time.

The Brain Tumour Research Centre of Excellence at the University of Plymouth is a hub for world-leading research into low-grade tumours including low-grade glioma, meningioma, and schwannoma. Renewed funding from the charity Brain Tumour Research will enable scientists to deepen their understanding of how these tumours develop and translate that knowledge into life-changing therapies.

The Family Heart Foundation, a leading research and advocacy organization, published new research in the American Journal of Preventive Cardiology revealing significant gaps in cholesterol management during 2022-23 among U.S. adults with atherosclerotic cardiovascular disease (ASCVD). Findings show that only 13% of adults with ASCVD were meeting three key components of optimal low-density lipoprotein-cholesterol (LDL-C) management, including receiving guideline-recommended therapy, consistently taking the therapy, and reaching an LDL-C level less than 70 mg/dL. According to the study, many factors contributed to this gap, including the low usage of non-statin therapies to treat LDL-C in high-risk patients.

Researchers at Okayama University have developed a novel photochemical macrolactonization that converts hydroxyaldehydes into macrolactones (ring sizes 7–21) using in-situ generated acyl bromide intermediates under purple LED light. This radical light-driven method bypasses conventional activating agents and opens a versatile, efficient pathway for constructing complex natural product frameworks—a promising advance for drug discovery and macrolide synthesis.

With a new $2.3 million, four-year grant from the National Institute of Biomedical Imaging and Bioengineering, part of the National Institutes of Health, researchers at Virginia Tech’s Fralin Biomedical Research Institute at VTC are developing tools and techniques for gathering high-quality brain function data during during parent-child interactions.